All Stories

  1. Navigating How to Initiate Tenapanor Therapy in the Real World

    Article • Kidney360, July 2024, Wolters Kluwer Health

    Dr Hirotaka Komaba

  2. Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease

    Article • Endocrinology and Metabolism, May 2024, Korean Endocrine Society (KAMJE)

    Dr Hirotaka Komaba

  3. Association of serum sodium levels with fractures and mortality in patients undergoing maintenance hemodialysis

    Article • Journal of Nephrology, March 2024, Springer Science + Business Media

    Dr Hirotaka Komaba

  4. Standardization of PTH measurement by LC-MS/MS: a promising solution for interassay variability

    Article • Kidney International, February 2024, Elsevier

    Dr Hirotaka Komaba

  5. Active Vitamin D Use and Fractures in Hemodialysis Patients: Results from the International DOPPS

    Article • Journal of Bone and Mineral Research, November 2023, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  6. Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease

    Article • Nephrology Dialysis Transplantation, May 2023, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  7. Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects

    Article • Clinical and Experimental Nephrology, March 2023, Springer Science + Business Media

    Dr Hirotaka Komaba

  8. Fibroblast growth factor 23‐Klotho and mineral metabolism in the first year after pediatric kidney transplantation: A single‐center prospective study

    Article • Pediatric Transplantation, December 2022, Wiley

    Dr Hirotaka Komaba

  9. Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2022, Endocrine Society

    Dr Hirotaka Komaba

  10. Renoprotection by GDF15 and Klotho: birds of a feather flock together

    Article • Kidney International, June 2022, Elsevier

    Dr Hirotaka Komaba

  11. Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study

    Article • Nephrology Dialysis Transplantation, March 2022, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  12. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2022, Endocrine Society

    Dr Hirotaka Komaba

  13. Serum Sclerostin Levels and Mortality in Hemodialysis Patients: An 8-Year Prospective Study

    Article • American Journal of Nephrology, January 2022, Karger Publishers

    Dr Hirotaka Komaba

  14. Jury still out on whether FGF23 is a direct contributor, a useful biomarker, or neither

    Article • Kidney International, November 2021, Elsevier

    Dr Hirotaka Komaba

  15. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

    Article • American Journal of Kidney Diseases, September 2021, Elsevier

    Dr Hirotaka Komaba

  16. Interrelationships Between Sclerostin, Secondary Hyperparathyroidism, and Bone Metabolism in Patients on Hemodialysis

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2021, Endocrine Society

    Dr Hirotaka Komaba

  17. Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS

    Article • Journal of Cachexia Sarcopenia and Muscle, June 2021, Wiley

    Dr Hirotaka Komaba

  18. Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study

    Article • Journal of Renal Nutrition, April 2021, Elsevier

    MD, PhD Aleix Cases, Dr Hirotaka Komaba

  19. Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study

    Article • Clinical Kidney Journal, July 2020, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  20. Corrigendum to “A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy”

    Article • Journal of Diabetes Research, June 2020, Hindawi Publishing Corporation

    Dr Hirotaka Komaba

  21. Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy

    Article • Journal of Bone and Mineral Metabolism, March 2020, Springer Science + Business Media

    Dr Hirotaka Komaba

  22. Magnesium as a Janus-faced inhibitor of calcification

    Article • Kidney International, March 2020, Elsevier

    Dr Hirotaka Komaba

  23. Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation

    Article • Kidney Medicine, January 2020, Elsevier

    Dr Hirotaka Komaba

  24. Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury

    Article • Kidney International, July 2019, Elsevier

    Dr Hirotaka Komaba

  25. A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy

    Article • Journal of Diabetes Research, February 2019, Hindawi Publishing Corporation

    Dr Hirotaka Komaba, Masafumi Fukagawa

  26. Additional evidence for the role of parathyroid hormone in adipose tissue browning

    Article • EBioMedicine, January 2019, Elsevier

    Dr Hirotaka Komaba

  27. Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018

    Article • Clinical and Experimental Nephrology, December 2018, Springer Science + Business Media

    Hideki Fujii, Dr Hirotaka Komaba

  28. The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels

    Article • Journal of the Endocrine Society, November 2018, Endocrine Society

    Dr Hirotaka Komaba

  29. A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients

    Article • Therapeutic Apheresis and Dialysis, October 2018, Wiley

    Dr Hirotaka Komaba, Masafumi Fukagawa

  30. Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS)

    Article • BMC Nephrology, October 2018, Springer Science + Business Media

    Dr Hirotaka Komaba

  31. Energy sensor as a new regulator of FGF23 synthesis

    Article • Kidney International, September 2018, Elsevier

    Dr Hirotaka Komaba

  32. Role of Klotho in bone and implication for CKD

    Article • Current Opinion in Nephrology & Hypertension, July 2018, Wolters Kluwer Health

    Dr Hirotaka Komaba

  33. Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients

    Article • Therapeutic Apheresis and Dialysis, May 2018, Wiley

    Masafumi Fukagawa, Dr Hirotaka Komaba

  34. Secondary Hyperparathyroidism and Protein-Energy Wasting in End-Stage Renal Disease

    Article • Therapeutic Apheresis and Dialysis, April 2018, Wiley

    Dr Hirotaka Komaba

  35. Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate

    Article • Nephrology Dialysis Transplantation, April 2018, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  36. Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism

    Article • Biochemical Pharmacology, December 2017, Elsevier

    Dr Hirotaka Komaba

  37. Magnesium as a new player in CKD: too little is as bad as too much?

    Article • Kidney International, November 2017, Elsevier

    Dr Hirotaka Komaba

  38. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders

    Article • Clinical Journal of the American Society of Nephrology, July 2017, American Society of Nephrology

    Dr Hirotaka Komaba

  39. Effects of klotho deletion from bone during chronic kidney disease

    Article • Bone, July 2017, Elsevier

    Dr Hirotaka Komaba

  40. Resurgence of parathyroidectomy

    Article • Current Opinion in Nephrology & Hypertension, July 2017, Wolters Kluwer Health

    Dr Hirotaka Komaba

  41. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction

    Article • Journal of Cachexia Sarcopenia and Muscle, June 2017, Wiley

    Masafumi Fukagawa, Dr Hirotaka Komaba

  42. MP674LOWER TRACP-5B DUE TO CALCIUM OVERLOAD IS ASSOCIATED WITH HIGHER MORTALITY IN MAINTENANCE HEMODIALYSIS PATIENTS

    Article • Nephrology Dialysis Transplantation, May 2017, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  43. SP363RELATIONSHIP BETWEEN SERUM SCLEROSTIN, BONE METABOLISM MARKERS, AND FRACTURE IN HEMODIALYSIS PATIENTS: TOKAI DIALYSIS COHORT STUDY

    Article • Nephrology Dialysis Transplantation, May 2017, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  44. Klotho expression in osteocytes regulates bone metabolism and controls bone formation

    Article • Kidney International, April 2017, Elsevier

    Dr Hirotaka Komaba

  45. Etelcalcetide for the treatment of secondary hyperparathyroidism

    Article • Expert Opinion on Pharmacotherapy, March 2017, Taylor & Francis

    Masafumi Fukagawa, Dr Hirotaka Komaba

  46. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism

    Article • Kidney International, March 2017, Elsevier

    Dr Hirotaka Komaba

  47. Klotho expression in long bones regulates FGF23 production during renal failure

    Article • The FASEB Journal, February 2017, Federation of American Societies For Experimental Biology (FASEB)

    Dr Hirotaka Komaba

  48. Management of secondary hyperparathyroidism: how and why?

    Article • Clinical and Experimental Nephrology, January 2017, Springer Science + Business Media

    Dr Hirotaka Komaba

  49. Chronic Kidney Disease-Mineral and Bone Disorder in Asia

    Article • Kidney Diseases, January 2017, Karger Publishers

    Dr Hirotaka Komaba

  50. Phosphate—a poison for humans?

    Article • Kidney International, October 2016, Elsevier

    Dr Hirotaka Komaba

  51. A Prospective Multicenter Randomized Controlled Study on Interleukin-6 Removal and Induction by a new Hemodialyzer With Improved Biocompatibility in Hemodialysis Patients: A Pilot Study

    Article • Therapeutic Apheresis and Dialysis, August 2016, Wiley

    Dr Hirotaka Komaba

  52. MP348ADDITION OF SEVELAMER AND MORTALITY: THE WORLDWIDE DOPPS STUDY

    Article • Nephrology Dialysis Transplantation, May 2016, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  53. PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer

    Article • Cell Metabolism, February 2016, Elsevier

    Dr Hirotaka Komaba

  54. Vitamin D and Klotho in Chronic Kidney Disease

    Article • January 2016, Springer Science + Business Media

    Dr Hirotaka Komaba

  55. The Prevalence of 25-hydroxyvitamin D Deficiency in Japanese Patients with Diabetic Nephropathy

    Article • Internal Medicine, January 2016, Japanese Society of Internal Medicine

    Dr Hirotaka Komaba

  56. The Authors Reply

    Article • Kidney International, September 2015, Elsevier

    Dr Hirotaka Komaba

  57. Cinacalcet and Clinical Outcomes in Dialysis

    Article • Seminars in Dialysis, August 2015, Wiley

    Masafumi Fukagawa, Dr Hirotaka Komaba

  58. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism

    Article • Kidney International, August 2015, Elsevier

    Dr Hirotaka Komaba

  59. Klotho expression in long bones is critical for FGF23 production during renal failure

    Article • Endocrine Abstracts, May 2015, Bioscientifica

    Dr Hirotaka Komaba

  60. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia

    Article • Nephrology Dialysis Transplantation, November 2014, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  61. Abnormal Mineral Metabolism and Mortality in Hemodialysis Patients With Secondary Hyperparathyroidism: Evidence From Marginal Structural Models Used to Adjust for Time-Dependent Confounding

    Article • American Journal of Kidney Diseases, June 2014, Elsevier

    Dr Hirotaka Komaba

  62. Case of generalized pustular psoriasis with end-stage renal disease successfully treated with granulocyte monocyte apheresis in combination with hemodialysis

    Article • The Journal of Dermatology, May 2014, Wiley

    Dr Hirotaka Komaba

  63. Impact of Parathyroidectomy on Serum FGF23 and Soluble Klotho in Hemodialysis Patients With Severe Secondary Hyperparathyroidism

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2014, Endocrine Society

    Dr Hirotaka Komaba

  64. Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder

    Article • Kidney International Supplements, December 2013, Elsevier

    Dr Hirotaka Komaba

  65. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways

    Article • Bone, October 2013, Elsevier

    Dr Hirotaka Komaba

  66. Dialysis: Effect of cinacalcet on survival—the saga continues

    Article • Nature Reviews Nephrology, July 2013, Nature

    Dr Hirotaka Komaba

  67. Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

    Article • Therapeutic Apheresis and Dialysis, June 2013, Wiley

    Hideki Fujii, Dr Hirotaka Komaba, Seiji Fukumoto

  68. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy

    Article • Expert Opinion on Pharmacotherapy, March 2013, Informa Healthcare

    Dr Hirotaka Komaba

  69. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan

    Article • Journal of Bone and Mineral Research, January 2013, Wiley

    Dr Hirotaka Komaba

  70. Parathyroid Function in Chronic Kidney Disease: Role of FGF23-Klotho Axis

    Article • January 2013, Karger Publishers

    Dr Hirotaka Komaba

  71. Cinacalcet Induces Apoptosis in Parathyroid Cells in Patients with Secondary Hyperparathyroidism: Histological and Cytological Analyses

    Article • Nephron Clinical Practice, January 2013, Karger Publishers

    Dr Hirotaka Komaba

  72. Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification?

    Article • Kidney International, December 2012, Elsevier

    Dr Hirotaka Komaba

  73. Cost-Effectiveness of Cinacalcet Hydrochloride for Hemodialysis Patients With Severe Secondary Hyperparathyroidism in Japan

    Article • American Journal of Kidney Diseases, August 2012, Elsevier

    Dr Hirotaka Komaba

  74. The role of FGF23 in CKD—with or without Klotho

    Article • Nature Reviews Nephrology, June 2012, Nature

    Dr Hirotaka Komaba

  75. 8. CKD-MBD

    Article • Nihon Naika Gakkai Zasshi, January 2012, Japanese Society of Internal Medicine

    Dr Hirotaka Komaba

  76. Role of Uremic Toxins and Oxidative Stress in the Development of Chronic Kidney Disease–Mineral and Bone Disorder

    Article • Journal of Renal Nutrition, January 2012, Elsevier

    Dr Hirotaka Komaba

  77. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism

    Article • Nephrology Dialysis Transplantation, December 2011, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  78. Diseases of the parathyroid gland in chronic kidney disease

    Article • Clinical and Experimental Nephrology, August 2011, Springer Science + Business Media

    Dr Hirotaka Komaba

  79. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

    Article • Nephrology Dialysis Transplantation, July 2011, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  80. Parathyroid Hormone Control Survey to Determine Inter-method and Inter-lab Variations in Japan

    Article • Therapeutic Apheresis and Dialysis, May 2011, Wiley

    Dr Hirotaka Komaba

  81. Parathyroidectomy Markedly Reduces Oxidative Stress in a Patient with Primary Hyperparathyroidism

    Article • Therapeutic Apheresis and Dialysis, May 2011, Wiley

    Dr Hirotaka Komaba

  82. Novel Electrochemiluminescence Immunoassay Exclusively for Full-length Parathyroid Hormone during Treatment with Cinacalcet for Secondary Hyperparathyroidism

    Article • Therapeutic Apheresis and Dialysis, May 2011, Wiley

    Dr Hirotaka Komaba

  83. Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan

    Article • Clinical Journal of the American Society of Nephrology, May 2011, American Society of Nephrology

    Hideki Fujii, Dr Hirotaka Komaba

  84. Is the road to survival paved with good mineral management?

    Article • Nature Reviews Nephrology, April 2011, Nature

    Dr Hirotaka Komaba

  85. Source Matters: From Phosphorus Load to Bioavailability

    Article • Clinical Journal of the American Society of Nephrology, February 2011, American Society of Nephrology

    Dr Hirotaka Komaba

  86. Vitamin D Receptor Activator Reduces Oxidative Stress in Hemodialysis Patients With Secondary Hyperparathyroidism

    Article • Therapeutic Apheresis and Dialysis, January 2011, Wiley

    Dr Hirotaka Komaba

  87. Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients

    Article • American Journal of Nephrology, January 2011, Karger Publishers

    Hideki Fujii, Dr Hirotaka Komaba

  88. Mineral Metabolism Management in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D

    Article • American Journal of Nephrology, January 2011, Karger Publishers

    Dr Hirotaka Komaba

  89. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges

    Article • Expert Opinion on Biological Therapy, November 2010, Informa Healthcare

    Dr Hirotaka Komaba

  90. Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future?

    Article • Kidney International, November 2010, Elsevier

    Dr Hirotaka Komaba

  91. The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions

    Article • Endocrine, October 2010, Springer Science + Business Media

    Hideki Fujii, Dr Hirotaka Komaba

  92. Cinacalcet Effectively Reduces Parathyroid Hormone Secretion and Gland Volume Regardless of Pretreatment Gland Size in Patients with Secondary Hyperparathyroidism

    Article • Clinical Journal of the American Society of Nephrology, August 2010, American Society of Nephrology

    Dr Hirotaka Komaba

  93. Amino-terminal form of parathyroid hormone in CKD

    Article • Kidney International, July 2010, Elsevier

    Dr Hirotaka Komaba

  94. Imaging and intervention of parathyroid hyperplasia

    Article • June 2010, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  95. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients

    Article • Kidney International, February 2010, Elsevier

    Hideki Fujii, Dr Hirotaka Komaba

  96. FGF23–parathyroid interaction: implications in chronic kidney disease

    Article • Kidney International, February 2010, Elsevier

    Dr Hirotaka Komaba

  97. Oxidative and Nitrosative Stress and Progression of Diabetic Nephropathy in Type 2 Diabetes

    Article • American Journal of Nephrology, January 2010, Karger Publishers

    Hideki Fujii, Dr Hirotaka Komaba

  98. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient

    Article • Nephrology Dialysis Transplantation, November 2009, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  99. Management of Mineral and Bone Disorder in Chronic Kidney Disease: Quo Vadis?

    Article • Therapeutic Apheresis and Dialysis, October 2009, Wiley

    Dr Hirotaka Komaba

  100. Towards Cost-effective Strategies for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Japan

    Article • Therapeutic Apheresis and Dialysis, October 2009, Wiley

    Dr Hirotaka Komaba

  101. Reprint of “Critical issues of PTH assays in CKD” [Bone 44 (2009) 666–670]

    Article • Bone, July 2009, Elsevier

    Dr Hirotaka Komaba

  102. Fetuin–mineral complex: a new potential biomarker for vascular calcification?

    Article • Kidney International, May 2009, Elsevier

    Dr Hirotaka Komaba

  103. Critical issues of PTH assays in CKD

    Article • Bone, April 2009, Elsevier

    Dr Hirotaka Komaba

  104. Reply

    Article • Nephrology Dialysis Transplantation, November 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  105. Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?

    Article • Nephrology Dialysis Transplantation, October 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  106. Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases

    Article • Clinical Kidney Journal, October 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  107. Impact of Cinacalcet Hydrochloride on the Achievement of the Japanese Society for Dialysis Therapy (JSDT) Guideline Targets: A post-hoc Analysis of the KRN1493 Study

    Article • Therapeutic Apheresis and Dialysis, October 2008, Wiley

    Dr Hirotaka Komaba

  108. The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism

    Article • Clinical Kidney Journal, July 2008, Oxford University Press (OUP)

    Hideki Fujii, Dr Hirotaka Komaba

  109. Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism

    Article • Clinical Kidney Journal, July 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  110. Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention

    Article • Clinical Kidney Journal, July 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  111. Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review

    Article • Clinical Kidney Journal, July 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  112. Reply

    Article • Nephrology Dialysis Transplantation, July 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  113. Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients

    Article • Therapeutic Apheresis and Dialysis, June 2008, Wiley

    Hideki Fujii, Dr Hirotaka Komaba

  114. Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient

    Article • Nephrology Dialysis Transplantation, February 2008, Oxford University Press (OUP)

    Dr Hirotaka Komaba

  115. Calcium, Phosphorus, Cardiovascular Events and All-cause Mortality in Hemodialysis Patients: A Single-center Retrospective Cohort Study to Reassess the Validity of the Japanese Society for Dialysis Therapy Guidelines

    Article • Therapeutic Apheresis and Dialysis, February 2008, Wiley

    Dr Hirotaka Komaba

  116. Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

    Article • Internal Medicine, January 2008, Japanese Society of Internal Medicine

    Dr Hirotaka Komaba

  117. Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer?

    Article • Nature Clinical Practice Nephrology, June 2007, Nature

    Dr Hirotaka Komaba

  118. Adiponectin Is Associated with Brain Natriuretic Peptide and Left Ventricular Hypertrophy in Hemodialysis Patients with Type 2 Diabetes Mellitus

    Article • Nephron Clinical Practice, January 2007, Karger Publishers

    Dr Hirotaka Komaba

  119. 5. Familial Hypocalciuric Hypercalcemia

    Article • Nihon Naika Gakkai Zasshi, January 2007, Japanese Society of Internal Medicine

    Dr Hirotaka Komaba

  120. Extensive deep vein thrombosis in a postpartum woman with Behçet's disease associated with nephrotic syndrome

    Article • Kidney International, January 2007, Elsevier

    Dr Hirotaka Komaba

  121. Increased Serum High-Molecular-Weight Complex of Adiponectin in Type 2 Diabetic Patients with Impaired Renal Function

    Article • American Journal of Nephrology, December 2006, Karger Publishers

    Dr Hirotaka Komaba

  122. Impact of plasma adiponectin concentration on left ventricular mass index in hemodialysis patients

    Article • Nihon Toseki Igakkai Zasshi, January 2006, Japanese Society for Dialysis Therapy

    Dr Hirotaka Komaba

  123. A surgical case of long-term hemodialysis patient with the infected renal-arterial pseudoaneurysma

    Article • Nihon Toseki Igakkai Zasshi, January 2006, Japanese Society for Dialysis Therapy

    Dr Hirotaka Komaba

  124. Nasal continuous positive airway pressure improved circadian pattern of blood pressure and glycemic control in a diabetic hemodialysis patient with obstructive sleep apnea syndrome

    Article • Nihon Toseki Igakkai Zasshi, January 2006, Japanese Society for Dialysis Therapy

    Dr Hirotaka Komaba

  125. Dialysis catheter-related bacteremia, intractable abdominal angina and pyogenic vertebral osteomyelitis developed in a hemodialysis patient

    Article • Nihon Toseki Igakkai Zasshi, January 2005, Japanese Society for Dialysis Therapy

    Dr Hirotaka Komaba